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PERSPECTIVE
One Group’s Historical Reflections on DNA Vaccine Development
Ellen F. Fynan,1 Shan Lu,2 and Harriet L. Robinson3,*
1Department of Biology, Worcester State College, Worcester, Massachusetts; 2Department of Medicine, University of Massachusetts Medical School, Worcester,
Massachusetts; and 3GeoVax, Inc., Smyrna, Georgia.
DNA vaccines were pioneered by several groups in the early 1990s. This article presents the reflections of
one of these groups on their work with retroviral vectors in chickens that contributed to the discovery and
early development of DNA vaccines. Although the findings were initially met with skepticism, the work
presented here combined with that of others founded a new method of vaccination: the direct inoculation
of purified DNA encoding the target antigen.
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IN 1992, OUR LABORATORY was one of the pioneers on
the use of in vivo DNA-expressed proteins to elicit
protective immune responses. As with many novel
concepts, this ‘‘radical’’ method of vaccination met
with skepticism and doubt. Jenner self-published
his use of variolation to protect against smallpox
because the Royal Society considered that they
might damage the Society’s reputation by pub-
lishing his findings in the Proceedings of the Royal
Society.1 So too, the idea of using DNA as a vaccine
was first considered questionable. However, con-
vincing experimental evidence from our laboratory
and others over the past 25 years has demon-
strated the powerful potential of this method for
immunization and contributed to the use of in vivo
expression of DNA-encoded proteins for gene ther-
apy, cancer immunotherapy, and monoclonal an-
tibody production.2–4
The development of live vaccinia virus as an ex-
pression vector and its use as a vaccine in 1982
generated interest in the use of viral vectors for
vaccination.5,6 Recognizing the potential of this
method andpossible extension to avian diseases, our
group inserted the gene for avian influenza hem-
agglutinin, the major target for protective antibody,
into a replication-competent avian retrovirus vec-
tor.7 Transfection of the recombinant retroviral
vector into chick embryo fibroblasts resulted in
production of the vector and expression of the in-
fluenza hemagglutinin insert for >2 weeks. In ex-
periments conducted in collaboration with Rob
Webster of St. Jude’s Children’s Research Hospital
(which had the appropriate BSL3 laboratory for
testing avian influenza virus infections in chickens),
the retroviral vector–based vaccine completely pro-
tected chickens against a lethal influenza virus
challenge.7 In contrast, birds within the control
group succumbed to influenza. Given this, we next
tested an infectious, replication-defective pseudo-
type of the retroviral vector for the ability to provide
protection. This replication-defective pseudotype,
despite inoculating <1·106 infectious units, also
achieved 100% protection, demonstrating that even
low titers of a replication-defective vector could
achieve protective immunity.
Retroviruses have DNA and RNA forms of their
genetic information: RNA in infectious virus and
DNA in infected cells. Given the ability of rela-
tively few infectious units of the infectious, repli-
cation defective pseudotype to achieve protection
and a growing body of evidence for successful
in vivo transfection,8,9 we tested the ability of the
DNA forms of both the replication-competent and
replication-defective vectors to achieve protection.
We made as much DNA as we could and asked Rob
to vaccinate chickens with 300lg of vaccine DNA
*Correspondence: Dr. Harriet L. Robinson, GeoVax, Inc., 1900 Lake Park Drive, Suite 380, Smyrna, GA 30080. E-mail: hrobinson@geovax.com
ª Ellen F. Fynan et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative
Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
966 j HUMAN GENE THERAPY, VOLUME 29 NUMBER 9 DOI: 10.1089/hum.2018.066Mary Ann Liebert, Inc.
or empty vector DNA (the control). Each chicken
received 300lg of DNA at weeks 0 and 4 delivered
by three routes (subcutaneous, intraperitoneal,
and intravenous). A lethal influenza virus chal-
lenge was administered at week 5. We learned that
our first DNA experiment had worked when Rob
left the message ‘‘Send more vaccine.’’ We had
achieved 100% protection in both groups of chick-
ens, receiving either the replication-competent or
the replication-defective vectors. We immediately
set out to repeat the trial, telling nobody of the re-
sult until a patent had been filed. Once we had
filed, we began to present the results, but these
were met with disdain and skepticism. The first
question at the summer 1992 American Society of
Virology meeting was ‘‘You don’t think this will
ever be useful, do you?’’ Our grants were triaged
and our manuscripts returned (despite Nature
sending the report to multiple reviewers). For-
tunately, our department chair, Guido Majno, a
pathologist with broad interests in the history of
science and medicine and author of the bestselling
book, The Healing Hand, recognized the potential
of what we were doing and provided departmental
funds to keep us going. We knew we were onto
something, and we kept going.
The new technology first achieved public accep-
tance at the fall 1992 Cold Spring Harbor Vaccine
meeting, ‘‘Modern Approaches to New Vaccines,’’
which was attended by a number of the early
players in DNA vaccines. We presented our pro-
tective studies in chickens andmice. Margaret Liu,
Jeff Ulmer, and John Donnelly of Merck showed
that protective cytotoxic T cells could be elicited,
David Weiner from the University of Pennsylvania
described the generation of Ab responses for hu-
man immunodeficiency virus type 1 (HIV-1), and
researchers from Vical presented their results on
introducing DNA into muscle. The attendees clus-
tered around the DNA posters. The field of DNA
vaccines had been born! That fall, the Department
of Agriculture awarded our first funding for DNA
vaccines, and Shan Lu, a new postdoctoral fellow in
the lab, received a Howard Hughes fellowship for
studying DNA-based immunizations. It would,
however, take another year and increasing so-
phistication in immunology on our part to ‘‘merit’’
National Institutes of Health funding.
Taken together, it was becoming clear that
transfection could occur in vivo and that low
numbers of cells expressing a plasmid were suffi-
cient to stimulate an immune response. However,
given the concern that an endogenous virus might
render our replication-defective retroviral vectors
infectious, we undertook in vivo antigen expression
with a non-retroviral DNA vector, comprised of a
mammalian expression plasmid with the gene for
the influenza hemagglutinin antigen under the
control of a strong eukaryotic promoter. These
studies readily replicated the success achieved
with the retroviral vectors.
With protection against disease shown in DNA-
vaccinated chickens, we moved our studies into
much more tractable mouse models. Influenza
hemagglutinin expressing plasmid DNA success-
fully protected BALB/c mice following intramuscu-
lar and intravenous inoculationsusing ahypodermic
needle and syringe; intranasal inoculations, using
nose drops; and epidermal inoculations using a
gene gun. A prototype gene gun (Accell) was ac-
quired from Agracetus (Middleton, WI) where it
had been developed primarily to introduce DNA
into plant cells and, later, live animals.10–12 In our
experiments, we used the gene gun to blast gold
particles coated with the plasmid DNA into the
shaved abdominal skin of mice. In earlier biolistic
studies, Stephen Johnston had used a gene gun to
deliver human growth hormone to the outer ears
of mice and realized that he had not affected
mouse growth but had elicited Ab to human
growth hormone.13 The use of the Agracetus gun
(the size of a refrigerator) generated a great deal of
excitement (and noise) within the department, but
did not allay suspicions about our laboratory’s
endeavors.
Our initial experiments in mice were highly
successful: 95% of the mice inoculated intramus-
cularly survived the lethal influenza virus chal-
lenge. Even more striking were the results of the
gene gun inoculations.Mice were protected against
an influenza challenge virus with 250–2,500 times
less plasmid DNA than with the other routes of
administration.14 These results—along with pio-
neering work by Jon Wolff of the University of
Wisconsin and Phillip Felgner of Vical on intra-
muscular delivery of DNA;15 Margaret Liu, Jeff
Ulmer, and John Donnelly at Merck, which had
licensed the delivery of ‘‘naked DNA’’ to muscle
fromVical;16 Stephen Johnston of the Southwestern
Medical Center on ballistic delivery of DNA to elicit
Ab;13,16 David Weiner of the University of Penn-
sylvania;17 Heather Davis and Bob Whalen of the
Pasteur Institute;18,19 Hildegund Ertl of the Wistar
Institute;20 and Britta Wahren of the Karolinska
Institute19—gained acceptance for this new vacci-
nation method and encouraged others to try this
novel avenue of vaccine research.21
Given the ease of DNA vaccine construction and
manufacture, early DNA vaccines had reached the
clinic within 5 years of the first demonstration of
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in vivo immunogenicity (Table 1). Despite the ex-
traordinarily rapid reduction of this new technique
to clinical use, we are now 25 years out and do not
have a single licensed DNA vaccine for humans.
Part of this is due to DNA vaccines having been
used for the development of vaccines for chronic
infections, such as HIV, tuberculosis, and malaria,
which are difficult targets for vaccination. A second
important factor is the low level of immune re-
sponses that are elicited by DNA vaccines when
used alone or without assisted delivery such as by
electroporation.
The elicitation of low-titer antibody responses
was evident in our earliest experiments in chicken
where large amounts of DNA (300lg of DNA)
raised essentially undetectable Ab responses. The
‘‘undetectable’’ Ab responses did undergo strong
anamnestic expansions post challenge, sufficiently
strong to protect against infections that could kill
within a week of challenge. These strong anam-
nestic responses differed from anamnestic re-
sponses primed by a natural infection by being
focused on the antigen primed by the vaccine, ra-
ther than the totality of the immunogenic proteins
of an infection.22
This characteristic of DNA vaccines, the elicita-
tion of low but specific responses, is the foundation
for the currently popular use of DNA to prime re-
sponses that are then boosted by a live vector,
peptide, or protein.23 In these heterologous prime-
boost regimens, the DNA focuses the immune
response on its vaccine insert, promotes antigen-
specific B-cell development at the germinal center
of lymph nodes, and activates the innate immune
system to promote acquired immunity.24,25 Live
vectors such as modified vaccinia Ankara are then
used to boost the memory response for the vaccine
antigens, which occurs largely to the exclusion of
the antigens present in the boosting vector. Protein
boosts are most effective for the epitopes that are
common to the DNA-expressed antigen and the
boost. In this case, the DNA-expressed antigen can
serve to focus the boost on epitopes that represent
the native antigen. These are readily preserved on
DNA-expressed proteins but trickier to preserve on
protein immunogens that need to undergo pro-
duction, purification, and storage.
Heterologous prime boosts can be highly effective
for eliciting high levels of CD8+ T cells26,27 and an-
tibody.28,29 They are, however, cumbersome for the
development of real-world vaccines because they
require two different products that need to be used
in the correct order. Thus, they can be expensive to
manufacture and deliver. Recently, however, suc-
cessful vaccination, including the generation of
neutralizing Ab, has been achieved in nonhuman
primates with a DNA vaccine for Zika virus using
only two intramuscular bioject deliveries of the
vaccine preparation.30 Following challenge, 95%
(17/18) of the animals had no detectable viremia.
Currently, this Zika virus DNA vaccine candidate
is in Phase I clinical trials (ClinicalTrials.gov
NCT02840487). This success reflects the high im-
munogenicity of the Zika glycoprotein, and sets a
precedent forDNA immunizationswith other highly
immunogenic proteins holding good promise for
success. Following electroporation, Ebola, Marburg,
and Middle East respiratory syndrome (MERS)
vaccines have shown promise in nonhuman prima-
tes,31,32 and theMERSvaccine has been advanced to
clinical trials (ClinicalTrials.gov NCT02670187).
As DNA vaccines have undergone development,
many advances have been made in DNA expres-
sion and delivery. Jet injectors,33 improved lipo-
somes,34,35 and electroporation36 have enhanced
responses through increased efficiency of DNA de-
livery. Work on expression cassettes has identified
promoters, enhancers, and introns that optimize
responses.37 Pathogen genes have been codon op-
timized for human usage to enhance expression.38
The elicitation of immune responses has been
modulated by removing (to tolerize)39 or increasing
(to enhance)40 the CpGmotifs in plasmid DNA that
stimulate innate responses.41 Extensive studies
have employed genetic (DNA-encoded) adjuvants to
enhance and shape immune responses.20,42 Gene
guns, however, have not advanced from being a tool
suited to the laboratory to general use so far, but
there is renewed effort by Deborah Fuller from the
University of Washington on this approach.
As for the authors, we are still using DNA for
vaccination. Two of us are using heterologous
prime-boost regimens for the development of a HIV
Table 1. Timeline for DNA vaccines
1992 Demonstration of the ability to elicit antibodya
1993 First protective studies in animals
1994 Naming of technology, WHOb
1995 First prophylactic Phase I human trialc
1996 FDA points to consider for DNA-based vaccinesd
1998 HIV, malaria, influenza, herpes, and hepatitis B virus vaccines
in clinical trials
aDemonstrated in a ‘‘gene therapy’’ experiment in which human growth
hormone was being delivered to mice to enhance growth.
bNames under consideration included genetic immunization, polynucle-
otide immunization, gene vaccines, and DNA vaccines.
cThis first prophylactic trial, a Merck plasmid expressing influenza
hemagglutinin, was never published due to it not having worked and Mary
Lou Clements-Mann of Johns Hopkins, its P.I., having died in the crash of
Swiss Air, flight 111.
dPoints to consider present guidelines for the manufacture of vaccines.
WHO, World Health Organization; FDA, Food and Drug Administration;
HIV, human immunodeficiency virus.
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vaccine. One of us (H.L.R.) is using the DNA as a
prime for modified vaccinia Ankara boosts.43–45 In
this case, the DNA facilitates the display of the
native form of the HIV Env on virus like particles.
Another (S.L.) is using DNA as a prime for gp120
protein subunit boosts as part of a polyvalent HIV
vaccine strategy. The last (E.F.F.) is teaching the
next generation of experimental biologists.
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